Login to Your Account

Xarelto more effective than warfarin for stroke prevention in Asian AF

By John Fox
Staff Writer

Friday, May 2, 2014
HONG KONG – The oral anticoagulant Xarelto (rivaroxaban, Johnson & Johnson) is more effective than warfarin for preventing stroke and intracranial hemorrhage (ICH), particularly in Asian patients with atrial fibrillation (AF), Chinese University of Hong Kong (CUHK) scientists have reported. Stroke is the leading cause of death in China, where it kills more than 1.5 million people each year. In Hong Kong, more than 20,000 stroke patients are admitted to hospital for treatment each year and more than 3,000 die, with many of the survivors being disabled. According to a recent CUHK study presented during the 14th Asian Oceanian Congress of Neurology in Macao, China, in March, AF has become one of the leading stroke causes in Hong Kong.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription